Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.42 |
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.41 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3918716 | 0.95 | DGKA (0.56) | DGKAPRSS1PRSS2PRSS3MAPT | |
| SCHEMBL27659710 | 0.95 | DGKA (0.56) | DGKAPRSS1PRSS2PRSS3MAPT | |
| SCHEMBL2193854 | 0.95 | DGKA (0.56) | DGKAPRSS1PRSS2PRSS3MAPT | |
| SCHEMBL9517306 | 0.95 | DGKA (0.56) | DGKAPRSS1PRSS2PRSS3MAPT | |
| Cetostearyl Alcohol SCHEMBL10864865 | 0.92 | DGKA (0.59) | DGKAPRSS1PRSS2PRSS3MAPT | |
| Isostearyl Alcohol SCHEMBL9710592 | 0.92 | DGKA (0.59) | DGKAPRSS1PRSS2PRSS3MAPT | |
| SCHEMBL27960835 | 0.89 | DGKA (0.62) | DGKAPRSS1PRSS2PRSS3MAPT | |
| SCHEMBL2196519 | 0.89 | DGKA (0.62) | DGKAPRSS1PRSS2PRSS3MAPT | |
| Dibutyl Sebacate SCHEMBL28833423 | 0.88 | DGKA (0.56) | DGKAPRSS1PRSS2PRSS3MAPT | |
| SCHEMBL3312964 | 0.86 | DGKA (0.47) | DGKAPRSS1PRSS2PRSS3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197672-A1 | COMPOSITION FOR INHIBITING SKIN PIGMENTATION THROUGH AUTOPHAGY ACTIVITY CONTAINING PROCYANIDIN A2 AND QUERCETIN, AS ACTIVE INGREDIENTS | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2024-06-20 | — | — | US | disclosed |
| US-20240180833-A1 | NANOVESICLES DERIVED FROM BACTERIA OF THE GENUS PARACOCCUS AND USE THEREOF | MD HEALTHCARE INC. (KR) | 2024-06-06 | — | — | US | disclosed |
| CN-117940109-A | Composition for preventing bromhidrosis | 持田制药株式会社 | 2024-04-26 | — | — | CN | disclosed |
| EP-4349351-A1 | LACTOBACILLUS PLANTARUM-DERIVED VESICLE AND USE THEREOF | MD Healthcare Inc. (KR) | 2024-04-10 | — | — | EP | disclosed |
| EP-4349354-A1 | EXTRACELLULAR VESICLES DERIVED FROM LACTOBACILLUS BACTERIA, AND USE THEREOF | MD Healthcare Inc. (KR) | 2024-04-10 | — | — | EP | disclosed |
| EP-4349352-A1 | LACTOBACILLUS ACIDOPHILUS-DERIVED VESICLE AND USE THEREOF | MD Healthcare Inc. (KR) | 2024-04-10 | — | — | EP | disclosed |
| EP-4349353-A1 | LACTOBACILLUS RHAMNOSUS-DERIVED VESICLE AND USES THEREOF | MD Healthcare Inc. (KR) | 2024-04-10 | — | — | EP | disclosed |
| US-20240099955-A1 | SKINCARE COMPOSITIONS AND METHODS OF USE THEREOF | HTL BIOTECHNOLOGY INNOVATION INC. | 2024-03-28 | — | — | US | disclosed |
| US-20240050538-A1 | PHARMACEUTICAL COMPOSITION FOR LONG-TERM STORAGE OF LIQUID FORMULATION OF BOTULINUM TOXIN | ATGC CO., LTD. (KR) | 2024-02-15 | — | — | US | disclosed |
| US-11896706-B2 | Composition for preventing hair loss or promoting hair growth, comprising, as active ingredient, mixed extract of cucumber, eggplant and snail extracts as active ingredient | OGADAL INC. (KR) | 2024-02-13 | — | — | US | disclosed |
| US-20060222616-A1 | Cosmetic composition comprising a and a lipopeptide | KANEKA CORPORATION (JP) | 2006-10-05 | — | — | US | disclosed |
| EP-1689494-A1 | AGENT FOR SKIN EXTERNAL USE CONTAINING SALT OF ASCORBIC ACID DERIVATIVE, METHOD FOR STABILIZING THE AGENT FOR SKIN EXTERNAL USE, AND STABILIZER | Showa Denko K.K. (JP) | 2006-08-16 | — | — | EP | disclosed |
| EP-1660025-A1 | COSMETIC COMPOSITION CONTAINING A POLYOXYETHYL COMBINATION AND A LIPOPEPTIDE | Showa Denko K.K. (JP) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005102267-A1 | AGENT FOR SKIN EXTERNAL USE CONTAINING TOCOPHEROL DERIVATIVE, ASCORBIC ACID DERIVATIVE AND SURFACE ACTIVE AGENT HAVING LIPOPEPTIDE STRUCTURE | SHOWA DENKO K.K. (JP) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005094777-A1 | EXTERNAL PREPARATION FOR SKIN | SHOWA DENKO K.K. (JP) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005095462-A1 | MOISTURE RETENTION POLYMER COMPOUND | SHOWA DENKO K.K. (JP) | 2005-10-13 | — | — | WO | disclosed |
| US-20050220744-A1 | Polysaccharide/functional compound complex | SHOWA DENKO K.K. | 2005-10-06 | — | — | US | disclosed |
| WO-2005089708-A1 | OIL-IN-WATER EMULSIFIED COMPOSITION, AND EXTERNAL PREPARATION FOR SKIN AND COSMETICS USING THE COMPOSITION | SHOWA DENKO K.K. (JP) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005034903-A1 | AGENT FOR SKIN EXTERNAL USE CONTAINING SALT OF ASCORBIC ACID DERIVATIVE, METHOD FOR STABILIZING THE AGENT FOR SKIN EXTERNAL USE, AND STABILIZER | SHOWA DENKO K.K. (JP) | 2005-04-21 | — | — | WO | disclosed |
| WO-2005020950-A1 | COSMETIC COMPOSITION COMPRISING A AND A LIPOPEPTIDE | SHOWA DENKO K.K. (JP) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197672-A1 | COMPOSITION FOR INHIBITING SKIN PIGMENTATION THROUGH AUTOPHAGY ACTIVITY CONTAINING PROCYANIDIN A2 AND QUERCETIN, AS ACTIVE INGREDIENTS | TYR, ATG7, BECN1 | DGKA 3324/4885PRSS1 1279/4885PRSS2 1084/4885 |
| US-20060222616-A1 | Cosmetic composition comprising a and a lipopeptide | CUTA, SMURF1, FABP4 | DGKA 91/4885PRSS1 2850/4885PRSS2 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.